Research in mice given 5-amino-1MQ showed a 7% reduction in body mass over 10 days without any changes in food intake, compared to controls
While research backs the customization of peptide therapy to personal biology as a route to enhanced effects, work with a clinician who understands reproductive endocrinology, use objective tracking and anticipate iteration
Marvin ME, Mason RP, Cashmore AM
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
If one is low, it can affect how the body uses the other
